{
  "page_0": "NEOPHARM\nInvestor\nRelations\n2024\nThe\nGlobal\nLeader\nIn\nSkin\nScience\n피부\n과학의\n선도기업\n네오팜\nNeopharm",
  "page_1": "NEOPHARM\nThe\nGlobal\nLeader\nIn\nSkin\nScience\n피부\n과학의\n선도기업\n네오팜\n네오팜은\n피부과학의\n선도기업으로서,\n끊임없는\n기술혁신으로\n인류공헌에\n앞장섭니다.\nEarnings\nSummary\nATOPALM\nATOPALM\nATOPALM\nTOP TO\nTOE\nWASH\n팝투토 워시\nFACIAL\n「OAMWASH\nMLELOTION\nMoisturisingShampco&BodyWash\n주요\n제품군\n매출\n현황\n영업이 로선\nATOPALM\n매출\n주요\n채널별\n매출\n현황\n세정 후에도 촉촉한 샘푸 경용 바스\n및\n손익\n현황\nI\nI\nMILE Skin Barrier Lotion\n수분 보증단 기능성 료선\nei\n=\nPANTHENOL\nATOPALM\nCREAM\nATOPALM\nInternative Deep-Hydration\nMLE\nCREAM\n집중 고보습 진정 크림\n엠엘이 크림\n기능성 화장품\nMLE Skin\nBarrier Cream\nMLE 피부보호막 가능성 크림\nPANTHENOL\nSTICK\nBALM\n판테놀 스틱 밤\nCalming Stick Balm\nForSensitiveAreas\n현장 부유 진정 스틱 빔",
  "page_2": "The\nGlobal\nLeader\nIn\nSkin\nScience\nNEOPHARM\n1. 2024년\n2분기\n경영성과\nEarnings\nSummary\n|\nAppendix\n매출\n및\n손익\n현황\n(연결)\n매출\n영업이익\n순이익\n306억원\n(YoY\n+25.0%)\n61억원\n(YoY\n-2.7%)\n58억원\n(YoY\n+7.6%)\n비중국\n중심\n수출\n성장\n지속\n매출\n믹스에\n따른\n원가\n상승\n영향\n외화환산이익\n증가\n영향\n30,621\n24,498\n6,273\n6,107\n5,883\n5,469\n+25.0%\n+7.6%\n(단위: 백만원)\n(단위: 백만원)\n(단위: 백만원)\n2023 2Q\n2024 2Q\n2023 2Q\n2024 2Q\n2023 2Q\n2024 2Q\nInvestor\nRelations\n2024\n3",
  "page_3": "The\nGlobal\nLeader\nIn\nSkin\nScience\nNEOPHARM\n1.2024년\n2분기\n경영성과\nEarnings\nSummary\n|\nAppendix\n주요\n채널별\n매출\n현황\n(별도)\n채널별 매출\n추이\n(단위:\n백만원)\n4,419\n.\n주요\n채널:\n외부몰,\n자사몰 등\n3,878\nOnline\n·\n매출액:\n88억\n/\n매출비중:29%\n3,669\n·\n전년\n동기\n대비\n역성장\n3,609\n3,676\n·\n주요\n채널:\n병의원,\nH&B\n등\n17,412\nOffline\n·\n매출액:\n174억\n/\n매출비중:\n57%\n15,339\n16,500\n11,388\n·\n전년\n동기\n대비\n53%\n성장\n10,941\n·\n주요\n권역:\n미주/아시아/중국/기타\n·\n매출액:\n44억\n/\n매출비중:\n14%\nExport\n9,449\n7,213\n8,220\n7,849\n8,850\n미주:\n8.7억\n/\n아시아.\n22억\n/중국.\n1.1억\n/기타.\n12.3억\n·\n전년\n동기\n대비\n22%\n성장\n2023 2Q\n2023 3Q\n2023 4Q\n2024 1Q\n2024 2Q\nInvestor\nRelations\n2024\n4\nOn line\nOff line\nExport",
  "page_4": "The\nGlobal\nLeader\nIn\nSkin\nScience\nNEOPHARM\n1. 2024년\n2분기\n경영성과\nEarnings\nSummary\n|\nAppendix\n주요\n제품군\n매출\n현황\n(별도)\n제품군별 매출\n추이\n(단위:\n백만원)\n·\n주요\n브랜드:\n아토팜,\n제로이드\nSkin\nCare\n·\n매출액:\n173억\n/\n매출비중:\n57%\n5,125\n·\n전년\n동기\n대비\n6%\n성장\n2,084\n3,395\n903\n4,840\n5,095\n4,641\n·\n주요\n브랜드:리얼베리어,\n티엘스\n3,498\n1,400\nFacial\nCare\n·\n매출액:\n33억\n/\n매출비중:\n11%\n3,352\n3,649\n·\n전년\n동기\n대비\n역성장\n3,645\n3,901\n3,968\n3,252\n·\n주요\n브랜드:\n더마비\nBody\n·\n매출액:\n48억\n/\n매출비중:\n16%\nCare\n·\n전년\n동기\n대비\n38%\n성장\n17,365\n16,400\n16,148\n16,224\n13,529\n.\n주요\n브랜드:\nOEM\n및\n기타\n브랜드\nOthers\n·\n매출액:51억\n/\n매출비중:\n17%\n·\n전년\n동기\n대비\n467%\n성장\n2023 2Q\n2023 3Q\n2023 4Q\n2024\n1Q\n2024 2Q\nInvestor\nRelations\n2024\n5\nSkin care\nFacial\nCare\nBody\nCare\nOthers",
  "page_5": "NEOPHARM\nThe\nGlobal\nLeader\nIn\nSkin\nScience\n피부\n과학의\n선도기업\n네오팜\n네오팜은\n피부과학의\n선도기업으로서,\n끊임없는\n기술혁신으로\n인류공헌에\n앞장섭니다.\nRealbarrier\nAppendix\nEXTREME\nCREAM\n익스트림 크림\nLight\nRealba\nAQUA\nSOOTHIN\nRealbarrier\nAMPOULE\nMAS\nRealbarrier\n아쿠아\n수딩 앰플 마스크\nRealbarrier\nAQUA\n1. 재무\n사항\n28ml/0.94ft.oz.\n65ml/2.19fl.oz.\nAQUA\nSOOTHING\nSOOTHING\nRealbarrier\nTONER\nCREAM\nEXTREME\n아쿠아 수딩 크린\n아후아 수단 토너\nCREAM\nEXTREME\nCREAM\n익스트림 크림\nOriginal\n익스드림 크림\nLight\n70ml/2.36fl.oz.\nRealbarrier\nEXTREME\nCREAM\n=\n믹스드림크림\nOriginal\n70ml/2.36fl.oz.\n=\n26ml : 2.19 fl. re.",
  "page_6": "The\nGlobal\nLeader\nIn\nSkin\nScience\nNEOPHARM\n1.\n재무\n사항\nEarnings\nSummary\n|\nAppendix\n요약\n재무상태표\n요약\n손익계산서\n구분(단위:\n억원)\n2020\n2021\n2022\n2023\n구분(단위:\n억원)\n2020\n2021\n2022\n2023\n유동자산\n1,136\n1,215\n1,313\n1,345\n매출액\n816\n879\n850\n971\n비유동자산\n194\n219\n241\n430\n매출원가\n230\n255\n267\n317\n자산총계\n1,330\n1,434\n1,553\n1,775\n매출총이익(률)\n586\n624\n584\n654\n(72%)\n(71%)\n(69%)\n(67%)\n유동부채\n149\n129\n131\n169\n판매비와관리비\n367\n400\n369\n401\n비유동부채\n4\n2\n0\n5\n219\n224\n214\n253\n부채총계\n153\n131\n131\n174\n영업이익(률)\n(27%)\n(26%)\n(25%)\n(26%)\n자본금\n41\n41\n41\n41\n영업외수익\n17\n20\n25\n49\n자본잉여금\n451\n457\n457\n457\n영업외비용\n6\n6\n6\n8\n자본조정\n(26)\n(32)\n(32)\n(32)\n법인세차감전순이익\n229\n238\n233\n294\n기타포괄손익누계액\n0\n(1)\n(5)\n(2)\n법인세비용\n48\n61\n63\n62\n이익잉여금\n711\n838\n961\n1,136\n자본총계\n1,177\n1,303\n1,422\n1,600\n당기순이익(률)\n(22%)\n181\n(20%)\n177\n(20%)\n170\n(24%)\n232\n주 : K-IFRS\n연결기준\nInvestor\nRelations\n2024\n7",
  "page_7": "NEOPHARM\n대전광역시\n유성구\n테크노로\n309-8\n주식회사\n네오팜\nTel.\n042\n864\n0043\nFax.\n042\n864\n0039\nwww.neopharm.co.kr\nNeopharm"
}